Breaking Typhoon Dolphin Approaches Japan’s Southern Islands, Disrupting Travel and Prompting Evacuations U.S.-Mexico Border Wall Project Continues Over a Decade After Initial Pledge Indianapolis Colts Sign Jonathan Taylor to Two-Year Contract Extension FDA Approves First mRNA Flu Vaccine for Individuals 50 and Older Meta Ordered to Pay $567 Million for Youth Mental Health Impacts

Friday August 7, 2026

Reporter

Eisai Inc.

5Articles Published

5Communities Covered

Published Articles

Press Release

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

Jul 14

Press Release

LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer’s Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment

Jul 14

Press Release

FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer’s Disease

Jul 13

Press Release

Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer’s Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer’s Association International Conference® (AAIC®) 2026

Jul 13

Press Release

LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer’s Disease Presented at the Alzheimer’s Association International Conference® (AAIC®) 2026

Jul 12